Literature DB >> 35350259

Recurrent erysipelas led to diagnosis of hereditary hemorrhagic telangiectasia.

Mari Yamaoka1, Yohei Kanzawa1, Shun Tatehara2, Koji Sasaki3, Shimpei Mizuki1, Jun Ohnishi1, Takahiro Nakajima1, Naoto Ishimaru1, Saori Kinami1.   

Abstract

Hereditary hemorrhagic telangiectasia (HHT) is a risk of infection, such as by brain abscess associated with pulmonary arteriovenous malformations. However, association between HHT and recurrent erysipelas is not well described. HHT can cause vessel malformations in organs, leading to various serious outcomes. Prophylactic treatment is effective, but many people with HHT are undiagnosed. HHT is not described as a risk factor for soft tissue infection, but may increase the risk of serious infections requiring hospitalization. Our 72-year-old female patient was admitted for recurrent erysipelas. Pulmonary nodules indicated pulmonary arteriovenous fistula on chest computed tomography. By recognizing this combination, although seemingly unrelated problems, we could diagnose HHT and the patient could receive adequate treatment to prevent life-threatening events. The recurrent erysipelas was likely associated with HHT. Recurrent erysipelas is an important presentation which may facilitate early diagnosis of HHT.
Copyright © 2022 InfezMed.

Entities:  

Keywords:  Osler-Weber-Rendu disease; epistaxis; pulmonary arteriovenous malformations

Year:  2022        PMID: 35350259      PMCID: PMC8929743          DOI: 10.53854/liim-3001-16

Source DB:  PubMed          Journal:  Infez Med        ISSN: 1124-9390


  17 in total

Review 1.  Cellulitis and Soft Tissue Infections.

Authors:  Rachel Bystritsky; Henry Chambers
Journal:  Ann Intern Med       Date:  2018-02-06       Impact factor: 25.391

2.  Infection prevention in patients with hereditary hemorrhagic telangiectasia.

Authors:  Juan Rodríguez-García; Roberto Zarrabeitia-Puente; Rafael Fernández-Santos; José Antonio García-Erce
Journal:  Haematologica       Date:  2018-10       Impact factor: 9.941

3.  Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America.

Authors:  Dennis L Stevens; Alan L Bisno; Henry F Chambers; E Patchen Dellinger; Ellie J C Goldstein; Sherwood L Gorbach; Jan V Hirschmann; Sheldon L Kaplan; Jose G Montoya; James C Wade
Journal:  Clin Infect Dis       Date:  2014-06-18       Impact factor: 9.079

4.  Hereditary hemorrhagic telangiectasia: children need screening too.

Authors:  Lynne A Sekarski; Lori A Spangenberg
Journal:  Pediatr Nurs       Date:  2011 Jul-Aug

5.  Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome).

Authors:  C L Shovlin; A E Guttmacher; E Buscarini; M E Faughnan; R H Hyland; C J Westermann; A D Kjeldsen; H Plauchu
Journal:  Am J Med Genet       Date:  2000-03-06

6.  Randomized, controlled, double-blinded clinical trial of effect of bevacizumab injection in management of epistaxis in hereditary hemorrhagic telangiectasia patients undergoing surgical cauterization.

Authors:  Ashoke R Khanwalkar; Aakanksha Rathor; Amelia K Read; Hassan Paknezhad; Yifei Ma; Peter H Hwang
Journal:  Int Forum Allergy Rhinol       Date:  2022-01-19       Impact factor: 5.426

Review 7.  Epistaxis: evaluation and treatment.

Authors:  Daniel J Morgan; Rick Kellerman
Journal:  Prim Care       Date:  2014-03       Impact factor: 2.907

8.  Immunological abnormalities associated with hereditary haemorrhagic telangiectasia.

Authors:  A Guilhem; C Malcus; B Clarivet; H Plauchu; S Dupuis-Girod
Journal:  J Intern Med       Date:  2013-07-04       Impact factor: 8.989

9.  Estimates of maternal risks of pregnancy for women with hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): suggested approach for obstetric services.

Authors:  C L Shovlin; V Sodhi; A McCarthy; P Lasjaunias; J E Jackson; M N Sheppard
Journal:  BJOG       Date:  2008-05-30       Impact factor: 6.531

10.  Hereditary Hemorrhagic Telangiectasia (HHT) and Survival: The Importance of Systematic Screening and Treatment in HHT Centers of Excellence.

Authors:  Els M de Gussem; Steven Kroon; Anna E Hosman; Johannes C Kelder; Martijn C Post; Repke J Snijder; Johannes J Mager
Journal:  J Clin Med       Date:  2020-11-06       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.